ACAD vs MCK
ACADIA Pharmaceuticals Inc. vs McKesson Corporation — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
62
Buy
VS
MCK
McKesson Corporation
57
Buy
| Metric | ACAD | MCK |
| AI Score |
62
|
57
|
| Price |
$29.50
|
$860.44
|
| P/E Ratio |
13.11×
|
22.89×
|
| ROE |
31.9%
|
-219.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
3.6%
|
| Debt / Equity |
0.06×
|
-2.76×
|
| Dividend Yield |
0.0%
|
0.4%
|
| RSI (14) |
59.6
|
50.5
|
| Beta |
0.845
|
0.307
|
| Expected Upside |
—
|
+4.1%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus MCK.
ACAD leads by 5 points.
ACAD scores 62/100 (Buy) versus MCK at 57/100 (Buy).
ACAD Committee View
60% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Risk Analyst remains cautious — bollinger bandwidth of 22.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Bollinger bandwidth of 22.8% signals elevated volatility — Risk
MCK Committee View
67% agreement
6 analysts
The primary driver is news sentiment is positive (+0.27 across 20 articles, 14d). The main limiting factor is current ratio of 0.85 is tight -- limited short-term liquidity cushion. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 39.4% shows genuine earnings power backing the valuation — Value
- EPS growing 49.1% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 4.3x prices in significant intangible value — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical